Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 355 4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

HomeRunHitterXXXXX Sep. 3 at 7:31 PM

$PULM some moron dhorting

1 · Reply

hiTHit Sep. 3 at 6:41 PM

$PULM We’re now in the 3rd quarter, and if the RS scam happens, they’ll drive the price down even further to steal our shares…

0 · Reply

Nakom Sep. 3 at 6:34 PM

$PULM Couldn’t resist. Picked up another 52 shares for a total of 82 shares today. Now own over 6,000. Ok, let’s make this reverse merger happen!!!

0 · Reply

Nakom Sep. 3 at 2:38 PM

$PULM Picked up another 30 shares. Thank you for dropping it down. All is good.

0 · Reply

Nakom Sep. 2 at 2:53 PM

$PULM Nice, they are walking it down. I’m a buyer at these prices.

0 · Reply

Nakom Sep. 2 at 2:40 PM

$PULM Picked up another 30 shares. All good.

0 · Reply

watchinglucipump Sep. 2 at 12:31 AM

$PULM @Nakom @Nakom This pump fraud is as desperate as ever. Theres no audiance here the company is over. Yet here’s this same dirtbag day after day year after year lying and pumping the latest pending catalysts that will never materialize.. unbelievable.. https://stocktwits.com/Nakom/message/663342209

1 · Reply

Nakom Sep. 1 at 3:09 PM

$PULM Somebody knows something!!!

1 · Reply

Nakom Aug. 31 at 8:06 PM

$PULM ok, so I finally got those 30 shares and then picked up another 30 shares. All good.

0 · Reply

Nakom Aug. 31 at 3:37 PM

$PULM No volume so far. Hoping to snag another 30 shares this morning at $1.47. It’s partial executed. Seems no one wants to give up shares at that price.

0 · Reply

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Aug 13, 2026, 8:00 AM EDT - 21 days ago

Pulmatrix Earnings release: Q2 2026

Aug 13, 2026, 8:00 AM EDT - 21 days ago

Pulmatrix Quarterly report: Q2 2026

Aug 7, 2026, 8:00 AM EDT - 27 days ago

Pulmatrix Registration statement: Registration filing

Jun 4, 2026, 8:00 AM EDT - 3 months ago

Pulmatrix Registration statement: Registration filing

2026-06-04T10:16:34.000Z - 3 months ago

Pulmatrix files to sell 490,910 shares of common stock for holders

May 15, 2026, 8:20 AM EDT - 3 months ago

Pulmatrix Announces First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 3 months ago

Pulmatrix Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Pulmatrix Earnings release: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

2026-03-26T12:10:12.000Z - 5 months ago

Pulmatrix to merge with Eos Senolytix

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

2026-03-02T13:06:59.000Z - 6 months ago

Pulmatrix announces Cullgen terminates merger agreement

Mar 2, 2026, 8:00 AM EST - 6 months ago

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Feb 26, 2026, 8:05 AM EST - 6 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Feb 26, 2026, 8:00 AM EST - 6 months ago

Pulmatrix Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Pulmatrix Earnings release: Q4 2025

2025-12-18T13:17:12.000Z - 8 months ago

Pulmatrix and Cullgen continue to pursue merger

Dec 18, 2025, 8:05 AM EST - 8 months ago

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

2025-10-16T12:21:23.000Z - 10 months ago

Pulmatrix reports Q3 EPS (24c) vs. (71c) last year

2025-10-16T12:10:51.000Z - 10 months ago

Pulmatrix to potentially divest its patent portfolio for iSPERSE technology

Oct 16, 2025, 8:05 AM EDT - 10 months ago

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Oct 16, 2025, 7:00 AM EDT - 10 months ago

Pulmatrix Quarterly report: Q3 2025

Oct 16, 2025, 7:00 AM EDT - 10 months ago

Pulmatrix Earnings release: Q3 2025

2025-08-06T12:16:43.000Z - 1 year ago

Pulmatrix to potentially divest its patent portfolio for iSPERSE technology

Aug 6, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Aug 5, 2025, 6:00 PM EDT - 1 year ago

Pulmatrix Quarterly report: Q2 2025

Aug 5, 2025, 6:00 PM EDT - 1 year ago

Pulmatrix Earnings release: Q2 2025

2025-06-25T15:20:32.000Z - 1 year ago

Pulmatrix trading resumes

2025-06-25T15:15:23.000Z - 1 year ago

Pulmatrix trading halted, volatility trading pause

2025-06-23T17:34:11.000Z - 1 year ago

Pulmatrix trading halted, volatility trading pause

2025-06-23T17:33:41.000Z - 1 year ago

Pulmatrix trading resumes

May 15, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 14, 2025, 6:00 PM EDT - 1 year ago

Pulmatrix Earnings release: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Pulmatrix Quarterly report: Q1 2025

May 9, 2025, 4:00 PM EDT - 1 year ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Pulmatrix Annual report: Q4 2024

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Pulmatrix Earnings release: Q4 2024

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

GRDX

2024-11-13T14:50:17.000Z - 1 year ago

Pulmatrix trading resumes

2024-11-13T14:07:00.000Z - 1 year ago

Pulmatrix announces merger agreement with Cullgen

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

2024-11-13T13:55:15.000Z - 1 year ago

Pulmatrix trading halted, news pending

Nov 13, 2024, 6:00 AM EST - 1 year ago

Pulmatrix Transcript: M&A Announcement

Nov 13, 2024, 6:00 AM EST - 1 year ago

Pulmatrix Slides: M&A Announcement

2024-11-08T15:35:37.000Z - 1 year ago

Pulmatrix reports Q3 EPS (71c) vs. ($1.03) last year

2024-11-08T15:35:10.000Z - 1 year ago

Pulmatrix sees cash runway into 4Q26

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 7:00 AM EST - 1 year ago

Pulmatrix Quarterly report: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Pulmatrix Earnings release: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Pulmatrix Proxy statement: Proxy Filing

Aug 13, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Pulmatrix Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Pulmatrix Earnings release: Q2 2024

May 29, 2024, 8:45 AM EDT - 2 years ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 17, 2024, 8:00 AM EDT - 2 years ago

Pulmatrix Registration statement: Registration Filing

May 15, 2024, 9:35 AM EDT - 2 years ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 7:00 AM EDT - 2 years ago

Pulmatrix Quarterly report: Q1 2024

May 10, 2024, 7:00 AM EDT - 2 years ago

Pulmatrix Earnings release: Q1 2024

Mar 28, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Pulmatrix Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Pulmatrix Earnings release: Q4 2023

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 8, 2023, 6:00 PM EST - 2 years ago

Pulmatrix Quarterly report: Q3 2023

Nov 8, 2023, 6:00 PM EST - 2 years ago

Pulmatrix Earnings release: Q3 2023

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Earnings release: Q2 2023

Jul 11, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 3 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Jun 15, 2023, 2:00 AM EDT - 3 years ago

Pulmatrix Press release: Study Update

Jun 5, 2023, 6:45 AM EDT - 3 years ago

Pulmatrix Slides: Corporate Presentation

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Pulmatrix Proxy statement: Proxy Filing

May 24, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Quarterly report: Q1 2023

May 12, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Earnings release: Q1 2023

May 2, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Annual report: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Earnings release: Q4 2022

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Feb 3, 2023, 7:00 AM EST - 3 years ago

Pulmatrix Slides: KOL Event

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 14, 2022, 7:00 AM EST - 3 years ago

Pulmatrix Quarterly report: Q3 2022

Nov 14, 2022, 7:00 AM EST - 3 years ago

Pulmatrix Earnings release: Q3 2022

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 10, 2022, 7:00 AM EDT - 4 years ago

Pulmatrix Quarterly report: Q2 2022

Aug 10, 2022, 7:00 AM EDT - 4 years ago

Pulmatrix Earnings release: Q2 2022

Aug 8, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 4 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Jun 11, 2022, 7:00 AM EDT - 4 years ago

Pulmatrix Quarterly report: Q1 2022

Jun 11, 2022, 7:00 AM EDT - 4 years ago

Pulmatrix Earnings release: Q1 2022

May 12, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 2, 2022, 8:00 AM EDT - 4 years ago

Pulmatrix Proxy statement: Proxy Filing

Apr 29, 2022, 8:00 AM EDT - 4 years ago

Pulmatrix Proxy statement: Proxy Filing

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

HomeRunHitterXXXXX Sep. 3 at 7:31 PM

$PULM some moron dhorting

1 · Reply

hiTHit Sep. 3 at 6:41 PM

$PULM We’re now in the 3rd quarter, and if the RS scam happens, they’ll drive the price down even further to steal our shares…

0 · Reply

Nakom Sep. 3 at 6:34 PM

$PULM Couldn’t resist. Picked up another 52 shares for a total of 82 shares today. Now own over 6,000. Ok, let’s make this reverse merger happen!!!

0 · Reply

Nakom Sep. 3 at 2:38 PM

$PULM Picked up another 30 shares. Thank you for dropping it down. All is good.

0 · Reply

Nakom Sep. 2 at 2:53 PM

$PULM Nice, they are walking it down. I’m a buyer at these prices.

0 · Reply

Nakom Sep. 2 at 2:40 PM

$PULM Picked up another 30 shares. All good.

0 · Reply

watchinglucipump Sep. 2 at 12:31 AM

1 · Reply

Nakom Sep. 1 at 3:09 PM

$PULM Somebody knows something!!!

1 · Reply

Nakom Aug. 31 at 8:06 PM

$PULM ok, so I finally got those 30 shares and then picked up another 30 shares. All good.

0 · Reply

Nakom Aug. 31 at 3:37 PM

$PULM No volume so far. Hoping to snag another 30 shares this morning at $1.47. It’s partial executed. Seems no one wants to give up shares at that price.

0 · Reply

hiTHit Aug. 31 at 3:35 PM

$PULM The only place on the stock market where you can catch your breath: the PULM board. Plenty of oxygen, pristine air where you can relax, and lush greenery—it’s practically a paradise; this is the PULM cemetery…

0 · Reply

Busstamove Aug. 30 at 3:20 AM

$PULM couldn’t help myself picked up another 91k shares gl all

3 · Reply

Nakom Aug. 28 at 7:18 PM

$PULM Couldn’t help myself. Picked up another 65 shares. Now I have an uneven amount. Oh well, guess I will just keep buying.

0 · Reply

hiTHit Aug. 28 at 4:47 PM

$PULM There is probably no one around, because everyone went to the doctor. The doctor asked what their problem was, and they told him that their only problem was being PULM shareholders…

2 · Reply

Nakom Aug. 27 at 1:48 PM

$PULM Nothing to see here today. Have a great 😊 day.

0 · Reply

Igotzthis Aug. 27 at 2:42 AM

$PULM Incoming S-4 approval. It could happen. I think Pulmatrix gotz this.

2 · Reply

Nakom Aug. 25 at 7:59 PM

$PULM Snagged another 64 shares to have a nice even number now. I’m locked and loaded now for the reverse merger. Have a great week everyone.

0 · Reply

hiTHit Aug. 25 at 3:39 PM

$PULM Following the experts' advice, I tried drinking a cup of coffee to calm down—actually, not just one cup, but 100—but I still can't seem to calm down. I guess the coffee went bad.🔊

2 · Reply

Nakom Aug. 25 at 12:49 PM

$PULM One day Closer to a revers merger with EOS. What a great opportunity for Pulmatrix legacy shareholders. Don’t know if you saw it yesterday but a subsidiary of Roche Genentech signed a $2.3 billion with South Korea's Hanmi Pharmaceutical for a phase 1 weight loss drug where you don’t lose muscle. Sound familiar.

1 · Reply

Nakom Aug. 24 at 1:59 PM

$PULM $2.20 will be the floor for the stock price before the reverse merger. All good. 👍

1 · Reply

arrosto Aug. 24 at 1:36 PM

$PULM Unfortunately PULM could be $1 by merger time

2 · Reply

Nakom Aug. 24 at 11:30 AM

$PULM Expecting news this week. All good!!!

0 · Reply

Market Cap	5.37M
Revenue (ttm)	0.00
Net Income (ttm)	-5.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	20,300
Avg Vol	19,346
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	0%
Beta	1.90
Analysts	Strong Buy
Price Target	$10.00